Joel Greenblatt Biomarin Pharmaceutical Inc Transaction History

Gotham Asset Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$76.22 - $98.51 $122,714 - $158,601	-1,610 Reduced 39.69%	2,446 $235,000
Q3 2023 Nov 14, 2023	BUY	$85.07 - $94.48 $345,043 - $383,210	4,056 New	4,056 $358,000
Q1 2023 May 15, 2023	BUY	$87.74 - $117.27 $329,726 - $440,700	3,758 New	3,758 $365,000
Q4 2021 Feb 14, 2022	SELL	$71.72 - $91.47 $232,444 - $296,454	-3,241 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$74.77 - $85.47 $242,329 - $277,008	3,241 New	3,241 $250,000
Q3 2020 Nov 16, 2020	SELL	$71.87 - $131.03 $419,864 - $765,477	-5,842 Closed	0 $0
Q2 2020 Aug 13, 2020	SELL	$79.55 - $124.22 $411,909 - $643,211	-5,178 Reduced 46.99%	5,842 $721,000
Q1 2020 May 15, 2020	BUY	$71.37 - $96.85 $204,118 - $276,991	2,860 Added 35.05%	11,020 $931,000
Q4 2019 Feb 14, 2020	BUY	$64.27 - $86.37 $524,443 - $704,779	8,160 New	8,160 $690,000
Q4 2017 Feb 14, 2018	SELL	$80.76 - $95.13 $289,928 - $341,516	-3,590 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$80.6 - $94.95 $289,354 - $340,870	3,590	3,590 $334,000

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Gotham Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Gotham Asset Management, LLC and Joel Greenblatt with notifications on news.